Jun 30, 2020
WWE News: Dolph Ziggler Says Otis Storyline Had Run Its Course, Discusses Drew McIntyre Feud
This news has been received from: inquisitr.com
All trademarks, copyrights, videos, photos and logos are owned by respective news sources. News stories, videos and live streams are from trusted sources.
According to Dolph Ziggler in a recent interview with Sports Illustrated, the decision to move him to Monday Night Raw had nothing to do with him, but the company felt it was time for a fresh start for him following his feud with Otis. The WWE superstar also believes that the time was right for him to move brands, as he had nothing left to do on Friday Night SmackDown.
Ziggler opened up about his recent storyline with Otis, Mandy Rose and Sonya Deville. In the storyline, Ziggler teamed with Rose to try and sabotage Rose and Otis’ relationship. The angle coincided with the COVID-19 pandemic, and Ziggler believes that it would have turned out much better if the circumstances were different.
“I feel like [the program between] myself and Otis had kind of run its course. I really liked working with Otis, Mandy and Sonya. If this were the old days and we were going five days a week and doing live events, we would have had even more chemistry and a really special thing. In this day and age, where it’s just a TV show in a closed studio, as young superstars, they came along very quickly. But I don’t know where else we could go with that, so I completely understand the move to Raw.”
Ziggler also said that he enjoyed the story that led to the match between him and Otis at WrestleMania 36. He described himself as more of a “mark” for storylines than wrestling matches, even though the in-ring contest between the pair did receive positive reviews from fans and pundits.
The superstar went on to say that WrestleMania was a big night, and the only thing they needed to make the match more special was thousands of fans cheering for Otis. After the match, he and Rose kissed and consummated a romance that had been blossoming for months.
Not @otiswwe' mom's fruitcake!! That's not very nice, @HEELZiggler. #SmackDown @WWE_MandyRose pic.twitter.com/k3Oqn8life
— WWE (@WWE) December 28, 2019
Since moving back to Monday Night Raw, Ziggler has been engaged in a rivalry with Drew McIntyre. When McIntyre returned to WWE and eventually got promoted to the main roster, he and Ziggler became tag team partners. However, McIntyre has since turned babyface and won the World Championship, and their history with each other makes them ideal adversaries.
According to Ziggler, however, the former allies are still similar to each other in the way they approach the business. He believes that their ambition, fitness levels and work ethic make them both stand out from many of their peers, and he hopes that their rivalry leads to a long match that steals the show.
News Source: inquisitr.com
COVID-19 : Coronavirus | A patient overcomes COVID-19 thanks to ruxolitinib, a drug used against cancer
The Josep Carreras Leukemia Foundation Center in Germany has cured a patient with COVID-19 thanks to a medicine used against cancer, he ruxolitinib, a drug that acts as an immune inhibitor. Andreas Neubauer, director of the center, located at the University Clinical Hospital of Marburg, explained that for the first time a person with coronavirus who suffers from acute respiratory distress overcomes the disease thanks to this drug.
“We knew from Chinese publications that the so-called cytokine storm characterizes patients with a severe and even fatal course of the disease, “ Neubauer indicates. He adds: “During a cytokine storm the body is flooded with substances that stimulate the immune system,” a reaction that damages tissue and facilitates the spread of the virus.
For this reason, the doctor believed that the patient could use ruxolitinib, It is initially used to treat cancer that inhibits the body’s enzymes involved in excessive inflammatory reactions. After the medication was delivered, the patient experienced a “rapid improvement in breathing and heart function” and remembers the success of acalabrutinib.Successfully tested with other patients
As it worked in this patient, the health center also tested it on other patients with coronavirus in serious condition. “In the end the response was positive in all the patients who received the anticancer drug for more than a week”, Professor Neubauer has stated. “The time between the start of ruxolitinib administration and the improvement in health is so short that it is reasonable to suppose that the drug contributed to the favorable clinical course,” he added.Scientific study to prove its effectiveness
Given the success experienced, ruxolitinib will now be tested in a clinical trial with more virus sufferers. The Center of the Josep Carreras Leukemia Foundation of Germany has planned a Scientific study in which the use of this immunological inhibitor to treat patients with coronavirus suffering from acute respiratory distress will be thoroughly investigated.